The US Patent and Trademark Office issued Patent No. 11,382,979 to Alnylam, according to complaints in the US District Court for the District of Delaware. The patent claims a class of lipid nanoparticles that contain certain cationic biodegradable lipids for use in delivering a nucleic acid, including mRNA, the suits say.
Alnylam says its ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.